Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline